Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
33589755
PubMed Central
PMC8324471
DOI
10.1038/s41375-021-01173-w
PII: 10.1038/s41375-021-01173-w
Knihovny.cz E-zdroje
- MeSH
- bcr-abl fúzní proteiny genetika MeSH
- časové faktory MeSH
- chronická myeloidní leukemie farmakoterapie genetika patologie MeSH
- indukce remise MeSH
- inhibitory proteinkinas škodlivé účinky MeSH
- klinické zkoušky jako téma metody MeSH
- lidé MeSH
- lokální recidiva nádoru chemicky indukované diagnóza epidemiologie MeSH
- nenasazení léčby statistika a číselné údaje MeSH
- prognóza MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa epidemiologie MeSH
- Názvy látek
- bcr-abl fúzní proteiny MeSH
- inhibitory proteinkinas MeSH
Department of Hematology Karolinska University Hospital Stockholm Sweden
Department of Hematology Oncology and Radiation Physics Skåne University Hospital Lund Sweden
Department of Hematology St Olavs Hospital Trondheim Norway
Department of Hematology Sunderby Hospital Luleå Sweden
Department of Hematology University Hospital Linköping Sweden
Department of Hematology University Hospital Umeå Sweden
Department of Medicine Faculty of Medicine and Health Örebro University Örebro Sweden
Department of Medicine Karolinska University Hospital Stockholm Sweden
Department of Public Health and Clinical Medicine Umeå University Umeå Sweden
Zobrazit více v PubMed
Dulucq S, Astrugue C, Etienne G, Mahon FX, Benard A. Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years. Br J Haematol. 2020;3:452–68. doi: 10.1111/bjh.16408. PubMed DOI
Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;6:747–57. doi: 10.1016/S1470-2045(18)30192-X. PubMed DOI
Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;5:424–30. doi: 10.1200/JCO.2012.48.5797. PubMed DOI
Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, et al. Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;3:298–305. doi: 10.1200/JCO.2016.68.2914. PubMed DOI
Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–35. doi: 10.1016/S1470-2045(10)70233-3. PubMed DOI
Rousselot P, Loiseau C, Delord M, Cayuela JM, Spentchian M. Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission. Blood Adv. 2010;13:3034–40. PubMed PMC
Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, et al. Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica. 2019;8:1589–96. doi: 10.3324/haematol.2018.205054. PubMed DOI PMC
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84. doi: 10.1038/s41375-020-0776-2. PubMed DOI PMC
